CA1339075C - Methodes et compositions pour l'administration dose-effet non invasive de medicaments lipophiles - Google Patents

Methodes et compositions pour l'administration dose-effet non invasive de medicaments lipophiles

Info

Publication number: CA1339075C
Authority: CA; Canada
Prior art keywords: drug; patient; lollipop; dose; insulin
Prior art date: 1989-09-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA000610329A

Other languages

English (en)

Inventor

Theodore H. Stanley

Brian Hague

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Utah Research Foundation Inc

Original Assignee

University of Utah Research Foundation Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-09-05

Filing date

1989-09-05

Publication date

1997-07-29

1989-09-05 Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc

1989-09-05 Priority to CA000610329A priority Critical patent/CA1339075C/fr

1997-07-29 Application granted granted Critical

1997-07-29 Publication of CA1339075C publication Critical patent/CA1339075C/fr

2014-07-29 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

229940079593 drug Drugs 0.000 title claims abstract description 238
239000003814 drug Substances 0.000 title claims abstract description 238
239000000203 mixture Substances 0.000 title claims abstract description 36
238000000034 method Methods 0.000 title abstract description 76
235000011475 lollipops Nutrition 0.000 claims abstract description 138
230000004044 response Effects 0.000 claims abstract description 18
230000002218 hypoglycaemic effect Effects 0.000 claims abstract description 17
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 80
102000004877 Insulin Human genes 0.000 claims description 40
108090001061 Insulin Proteins 0.000 claims description 40
229940125396 insulin Drugs 0.000 claims description 40
210000000214 mouth Anatomy 0.000 claims description 35
239000011159 matrix material Substances 0.000 claims description 34
229960004943 ergotamine Drugs 0.000 claims description 21
OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 claims description 21
XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 claims description 21
238000011282 treatment Methods 0.000 claims description 20
208000002193 Pain Diseases 0.000 claims description 19
238000010521 absorption reaction Methods 0.000 claims description 19
208000019695 Migraine disease Diseases 0.000 claims description 17
150000001720 carbohydrates Chemical class 0.000 claims description 15
210000003238 esophagus Anatomy 0.000 claims description 14
206010027599 migraine Diseases 0.000 claims description 14
210000004400 mucous membrane Anatomy 0.000 claims description 11
210000003800 pharynx Anatomy 0.000 claims description 11
239000000463 material Substances 0.000 claims description 8
208000013016 Hypoglycemia Diseases 0.000 claims description 7
238000004090 dissolution Methods 0.000 claims description 6
238000010253 intravenous injection Methods 0.000 claims description 4
230000009467 reduction Effects 0.000 claims description 4
238000002844 melting Methods 0.000 claims description 3
230000008018 melting Effects 0.000 claims description 3
238000003780 insertion Methods 0.000 claims description 2
230000037431 insertion Effects 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
230000000694 effects Effects 0.000 abstract description 54
208000024891 symptom Diseases 0.000 abstract description 24
239000002111 antiemetic agent Substances 0.000 abstract description 22
229940124538 antidiuretic agent Drugs 0.000 abstract description 20
229940121375 antifungal agent Drugs 0.000 abstract description 19
230000002686 anti-diuretic effect Effects 0.000 abstract description 18
239000003160 antidiuretic agent Substances 0.000 abstract description 18
229940124630 bronchodilator Drugs 0.000 abstract description 14
230000000843 anti-fungal effect Effects 0.000 abstract description 12
230000002196 ecbolic effect Effects 0.000 abstract description 12
230000003474 anti-emetic effect Effects 0.000 abstract description 11
230000002460 anti-migrenic effect Effects 0.000 abstract description 11
239000000939 antiparkinson agent Substances 0.000 abstract description 10
230000001262 anti-secretory effect Effects 0.000 abstract description 9
230000000648 anti-parkinson Effects 0.000 abstract description 8
-1 hypoglycemic Substances 0.000 abstract description 3
206010047700 Vomiting Diseases 0.000 description 30
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 30
235000009508 confectionery Nutrition 0.000 description 29
230000003389 potentiating effect Effects 0.000 description 27
238000002347 injection Methods 0.000 description 25
239000007924 injection Substances 0.000 description 25
101800000989 Oxytocin Proteins 0.000 description 23
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 23
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 23
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 23
229960001723 oxytocin Drugs 0.000 description 23
235000009499 Vanilla fragrans Nutrition 0.000 description 20
244000263375 Vanilla tahitensis Species 0.000 description 20
235000012036 Vanilla tahitensis Nutrition 0.000 description 20
230000008673 vomiting Effects 0.000 description 20
VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 19
229960004022 clotrimazole Drugs 0.000 description 19
210000004185 liver Anatomy 0.000 description 19
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 18
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 18
239000004615 ingredient Substances 0.000 description 17
229960004502 levodopa Drugs 0.000 description 17
238000002360 preparation method Methods 0.000 description 16
229960000278 theophylline Drugs 0.000 description 15
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 14
210000004369 blood Anatomy 0.000 description 14
239000008280 blood Substances 0.000 description 14
208000037805 labour Diseases 0.000 description 14
229930006000 Sucrose Natural products 0.000 description 13
239000005720 sucrose Substances 0.000 description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
210000002700 urine Anatomy 0.000 description 12
108010011485 Aspartame Proteins 0.000 description 11
206010028813 Nausea Diseases 0.000 description 11
208000018737 Parkinson disease Diseases 0.000 description 11
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 11
229940125683 antiemetic agent Drugs 0.000 description 11
239000003429 antifungal agent Substances 0.000 description 11
239000000605 aspartame Substances 0.000 description 11
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 11
235000010357 aspartame Nutrition 0.000 description 11
229960003438 aspartame Drugs 0.000 description 11
230000008901 benefit Effects 0.000 description 11
235000014633 carbohydrates Nutrition 0.000 description 11
230000008693 nausea Effects 0.000 description 11
DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 10
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
WVVSZNPYNCNODU-XTQGRXLLSA-N Lysergic acid propanolamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-XTQGRXLLSA-N 0.000 description 10
235000006679 Mentha X verticillata Nutrition 0.000 description 10
235000002899 Mentha suaveolens Nutrition 0.000 description 10
235000001636 Mentha x rotundifolia Nutrition 0.000 description 10
206010030216 Oesophagitis Diseases 0.000 description 10
108091028664 Ribonucleotide Proteins 0.000 description 10
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 10
229910052782 aluminium Inorganic materials 0.000 description 10
206010012601 diabetes mellitus Diseases 0.000 description 10
208000006881 esophagitis Diseases 0.000 description 10
239000008103 glucose Substances 0.000 description 10
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 10
239000003826 tablet Substances 0.000 description 10
108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 9
229920002774 Maltodextrin Polymers 0.000 description 9
239000005913 Maltodextrin Substances 0.000 description 9
244000007021 Prunus avium Species 0.000 description 9
235000010401 Prunus avium Nutrition 0.000 description 9
235000014441 Prunus serotina Nutrition 0.000 description 9
229940035034 maltodextrin Drugs 0.000 description 9
229940100256 oxtriphylline Drugs 0.000 description 9
RLANKEDHRWMNRO-UHFFFAOYSA-M oxtriphylline Chemical compound C[N+](C)(C)CCO.O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 RLANKEDHRWMNRO-UHFFFAOYSA-M 0.000 description 9
239000002863 oxytocic agent Substances 0.000 description 9
239000000243 solution Substances 0.000 description 9
WVVSZNPYNCNODU-CJBNDPTMSA-N Ergometrine Natural products C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-CJBNDPTMSA-N 0.000 description 8
OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 8
208000004880 Polyuria Diseases 0.000 description 8
206010038687 Respiratory distress Diseases 0.000 description 8
230000008602 contraction Effects 0.000 description 8
229960001405 ergometrine Drugs 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
229960001474 meclozine Drugs 0.000 description 8
230000004060 metabolic process Effects 0.000 description 8
238000010992 reflux Methods 0.000 description 8
210000002784 stomach Anatomy 0.000 description 8
239000002731 stomach secretion inhibitor Substances 0.000 description 8
230000009885 systemic effect Effects 0.000 description 8
210000004291 uterus Anatomy 0.000 description 8
206010019233 Headaches Diseases 0.000 description 7
239000003472 antidiabetic agent Substances 0.000 description 7
239000002282 antimigraine agent Substances 0.000 description 7
208000006673 asthma Diseases 0.000 description 7
210000003169 central nervous system Anatomy 0.000 description 7
230000002496 gastric effect Effects 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
206010061324 Oral fungal infection Diseases 0.000 description 6
239000000168 bronchodilator agent Substances 0.000 description 6
229960004205 carbidopa Drugs 0.000 description 6
TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 6
239000006071 cream Substances 0.000 description 6
229960004281 desmopressin Drugs 0.000 description 6
NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
201000006549 dyspepsia Diseases 0.000 description 6
231100000869 headache Toxicity 0.000 description 6
239000000843 powder Substances 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
BJFIDCADFRDPIO-DZCXQCEKSA-N (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentazacycloeicos-4-yl]-oxomethyl]-2-pyrrolidinecarboxamide Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1 BJFIDCADFRDPIO-DZCXQCEKSA-N 0.000 description 5
108010048179 Lypressin Proteins 0.000 description 5
208000007027 Oral Candidiasis Diseases 0.000 description 5
206010044565 Tremor Diseases 0.000 description 5
102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 5
230000009471 action Effects 0.000 description 5
230000002411 adverse Effects 0.000 description 5
229940125684 antimigraine agent Drugs 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
201000010064 diabetes insipidus Diseases 0.000 description 5
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 5
238000001647 drug administration Methods 0.000 description 5
208000000718 duodenal ulcer Diseases 0.000 description 5
210000001035 gastrointestinal tract Anatomy 0.000 description 5
208000024798 heartburn Diseases 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
229960003837 lypressin Drugs 0.000 description 5
230000008569 process Effects 0.000 description 5
229960003712 propranolol Drugs 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 5
229960004291 sucralfate Drugs 0.000 description 5
230000009747 swallowing Effects 0.000 description 5
IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 4
208000009079 Bronchial Spasm Diseases 0.000 description 4
208000014181 Bronchial disease Diseases 0.000 description 4
206010006482 Bronchospasm Diseases 0.000 description 4
206010017533 Fungal infection Diseases 0.000 description 4
208000031888 Mycoses Diseases 0.000 description 4
229940035678 anti-parkinson drug Drugs 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
108091008690 chemoreceptors Proteins 0.000 description 4
230000018044 dehydration Effects 0.000 description 4
238000006297 dehydration reaction Methods 0.000 description 4
229960003133 ergot alkaloid Drugs 0.000 description 4
239000007788 liquid Substances 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
235000012054 meals Nutrition 0.000 description 4
239000002831 pharmacologic agent Substances 0.000 description 4
239000006187 pill Substances 0.000 description 4
230000035935 pregnancy Effects 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
210000003296 saliva Anatomy 0.000 description 4
239000000126 substance Substances 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 description 3
206010001541 Akinesia Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
241000233866 Fungi Species 0.000 description 3
208000018525 Postpartum Hemorrhage Diseases 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
208000007107 Stomach Ulcer Diseases 0.000 description 3
208000025865 Ulcer Diseases 0.000 description 3
208000036029 Uterine contractions during pregnancy Diseases 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
229960002845 desmopressin acetate Drugs 0.000 description 3
239000003925 fat Substances 0.000 description 3
230000037406 food intake Effects 0.000 description 3
230000002538 fungal effect Effects 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
229940126904 hypoglycaemic agent Drugs 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
238000010255 intramuscular injection Methods 0.000 description 3
210000002429 large intestine Anatomy 0.000 description 3
229960000988 nystatin Drugs 0.000 description 3
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 3
239000011591 potassium Substances 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
210000000813 small intestine Anatomy 0.000 description 3
230000035882 stress Effects 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 2
BFCDFTHTSVTWOG-YLJYHZDGSA-N (1S,2R)-2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol Chemical compound CCCCCCCCN[C@H](C)[C@@H](O)C1=CC=C(SC(C)C)C=C1 BFCDFTHTSVTWOG-YLJYHZDGSA-N 0.000 description 2
KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 2
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
229930182837 (R)-adrenaline Natural products 0.000 description 2
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
BVPWJMCABCPUQY-UHFFFAOYSA-N 4-amino-5-chloro-2-methoxy-N-[1-(phenylmethyl)-4-piperidinyl]benzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1CCN(CC=2C=CC=CC=2)CC1 BVPWJMCABCPUQY-UHFFFAOYSA-N 0.000 description 2
206010067484 Adverse reaction Diseases 0.000 description 2
206010063659 Aversion Diseases 0.000 description 2
IROWCYIEJAOFOW-UHFFFAOYSA-N DL-Isoprenaline hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 IROWCYIEJAOFOW-UHFFFAOYSA-N 0.000 description 2
208000001380 Diabetic Ketoacidosis Diseases 0.000 description 2
208000012661 Dyskinesia Diseases 0.000 description 2
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
229920002527 Glycogen Polymers 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
208000001953 Hypotension Diseases 0.000 description 2
HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
206010028735 Nasal congestion Diseases 0.000 description 2
241001290151 Prunus avium subsp. avium Species 0.000 description 2
206010039101 Rhinorrhoea Diseases 0.000 description 2
206010043458 Thirst Diseases 0.000 description 2
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 2
108010004977 Vasopressins Proteins 0.000 description 2
102000002852 Vasopressins Human genes 0.000 description 2
240000008042 Zea mays Species 0.000 description 2
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
235000002017 Zea mays subsp mays Nutrition 0.000 description 2
JSZILQVIPPROJI-CEXWTWQISA-N [(2R,3R,11bS)-3-(diethylcarbamoyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] acetate Chemical compound C1CC2=CC(OC)=C(OC)C=C2[C@H]2N1C[C@@H](C(=O)N(CC)CC)[C@H](OC(C)=O)C2 JSZILQVIPPROJI-CEXWTWQISA-N 0.000 description 2
206010000059 abdominal discomfort Diseases 0.000 description 2
230000003187 abdominal effect Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000006838 adverse reaction Effects 0.000 description 2
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
229930013930 alkaloid Natural products 0.000 description 2
229960003556 aminophylline Drugs 0.000 description 2
FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 2
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
229940092705 beclomethasone Drugs 0.000 description 2
229960004564 benzquinamide Drugs 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
235000019693 cherries Nutrition 0.000 description 2
230000035606 childbirth Effects 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
230000001010 compromised effect Effects 0.000 description 2
235000005822 corn Nutrition 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
229960002819 diprophylline Drugs 0.000 description 2
238000009826 distribution Methods 0.000 description 2
229960003638 dopamine Drugs 0.000 description 2
KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
229960005139 epinephrine Drugs 0.000 description 2
230000008921 facial expression Effects 0.000 description 2
229960000676 flunisolide Drugs 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
230000006870 function Effects 0.000 description 2
210000004051 gastric juice Anatomy 0.000 description 2
208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
208000030304 gastrointestinal bleeding Diseases 0.000 description 2
229940096919 glycogen Drugs 0.000 description 2
230000005484 gravity Effects 0.000 description 2
230000010224 hepatic metabolism Effects 0.000 description 2
201000001421 hyperglycemia Diseases 0.000 description 2
230000036543 hypotension Effects 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000007917 intracranial administration Methods 0.000 description 2
229960001268 isoetarine Drugs 0.000 description 2
230000003907 kidney function Effects 0.000 description 2
230000003908 liver function Effects 0.000 description 2
210000000111 lower esophageal sphincter Anatomy 0.000 description 2
LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 2
229960001186 methysergide Drugs 0.000 description 2
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 2
229960004503 metoclopramide Drugs 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
230000037023 motor activity Effects 0.000 description 2
230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 2
239000002547 new drug Substances 0.000 description 2
229960002657 orciprenaline Drugs 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000035699 permeability Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
230000001144 postural effect Effects 0.000 description 2
WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 2
229960003111 prochlorperazine Drugs 0.000 description 2
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 2
230000011514 reflex Effects 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
230000000284 resting effect Effects 0.000 description 2
239000011369 resultant mixture Substances 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
229960002052 salbutamol Drugs 0.000 description 2
230000028327 secretion Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
241000894007 species Species 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
229960003967 suloctidil Drugs 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
229960000195 terbutaline Drugs 0.000 description 2
FEZBIKUBAYAZIU-UHFFFAOYSA-N trimethobenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC=2C=CC(OCCN(C)C)=CC=2)=C1 FEZBIKUBAYAZIU-UHFFFAOYSA-N 0.000 description 2
229960004161 trimethobenzamide Drugs 0.000 description 2
230000036269 ulceration Effects 0.000 description 2
229960003726 vasopressin Drugs 0.000 description 2
206010000087 Abdominal pain upper Diseases 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010003011 Appendicitis Diseases 0.000 description 1
201000008283 Atrophic Rhinitis Diseases 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
206010006240 Breast engorgement Diseases 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
206010006784 Burning sensation Diseases 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
206010007134 Candida infections Diseases 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
208000018152 Cerebral disease Diseases 0.000 description 1
206010008479 Chest Pain Diseases 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
108090000317 Chymotrypsin Proteins 0.000 description 1
206010009192 Circulatory collapse Diseases 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
206010010970 Cor pulmonale chronic Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
229920002245 Dextrose equivalent Polymers 0.000 description 1
206010012607 Diabetes mellitus inadequate control Diseases 0.000 description 1
208000002230 Diabetic coma Diseases 0.000 description 1
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
206010013786 Dry skin Diseases 0.000 description 1
206010049119 Emotional distress Diseases 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
208000017701 Endocrine disease Diseases 0.000 description 1
206010049656 Fungal oesophagitis Diseases 0.000 description 1
206010018473 Glycosuria Diseases 0.000 description 1
208000034507 Haematemesis Diseases 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
208000006083 Hypokinesia Diseases 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010027423 Metabolic alkalosis Diseases 0.000 description 1
206010027603 Migraine headaches Diseases 0.000 description 1
208000002740 Muscle Rigidity Diseases 0.000 description 1
206010062575 Muscle contracture Diseases 0.000 description 1
206010028748 Nasal obstruction Diseases 0.000 description 1
206010029216 Nervousness Diseases 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
239000000006 Nitroglycerin Substances 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000027089 Parkinsonian disease Diseases 0.000 description 1
206010034010 Parkinsonism Diseases 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
206010035669 Pneumonia aspiration Diseases 0.000 description 1
229920002396 Polyurea Polymers 0.000 description 1
206010036246 Post abortion haemorrhage Diseases 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
206010071368 Psychological trauma Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
208000035977 Rare disease Diseases 0.000 description 1
206010039088 Rhinitis atrophic Diseases 0.000 description 1
208000036071 Rhinorrhea Diseases 0.000 description 1
206010039424 Salivary hypersecretion Diseases 0.000 description 1
244000082988 Secale cereale Species 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
206010057362 Underdose Diseases 0.000 description 1
206010047281 Ventricular arrhythmia Diseases 0.000 description 1
206010047709 Vomiting psychogenic Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229940069428 antacid Drugs 0.000 description 1
239000003159 antacid agent Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
201000009408 aspiration pneumonitis Diseases 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
238000005452 bending Methods 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
230000036471 bradycardia Effects 0.000 description 1
208000006218 bradycardia Diseases 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
230000003182 bronchodilatating effect Effects 0.000 description 1
230000007883 bronchodilation Effects 0.000 description 1
201000003984 candidiasis Diseases 0.000 description 1
230000023852 carbohydrate metabolic process Effects 0.000 description 1
235000021256 carbohydrate metabolism Nutrition 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
201000001352 cholecystitis Diseases 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
231100000749 chronicity Toxicity 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
208000006111 contracture Diseases 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
229960005156 digoxin Drugs 0.000 description 1
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
230000010339 dilation Effects 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
230000009429 distress Effects 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000035622 drinking Effects 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
230000037336 dry skin Effects 0.000 description 1
230000002183 duodenal effect Effects 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
229940035564 duration Drugs 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
201000005662 fungal esophagitis Diseases 0.000 description 1
230000005021 gait Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000001905 globus pallidus Anatomy 0.000 description 1
229960003711 glyceryl trinitrate Drugs 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
231100000334 hepatotoxic Toxicity 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
201000008980 hyperinsulinism Diseases 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
230000003483 hypokinetic effect Effects 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
230000036737 immune function Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
230000007794 irritation Effects 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000007775 late Effects 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
230000004132 lipogenesis Effects 0.000 description 1
230000004130 lipolysis Effects 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000019989 milk ejection Effects 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
230000004899 motility Effects 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000003365 myofibril Anatomy 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
208000010753 nasal discharge Diseases 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
210000004237 neck muscle Anatomy 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
235000015205 orange juice Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000012856 packing Methods 0.000 description 1
235000019629 palatability Nutrition 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
230000008447 perception Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000022558 protein metabolic process Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
239000006215 rectal suppository Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
230000004202 respiratory function Effects 0.000 description 1
230000001020 rhythmical effect Effects 0.000 description 1
239000012487 rinsing solution Substances 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
208000026451 salivation Diseases 0.000 description 1
230000035807 sensation Effects 0.000 description 1
235000019615 sensations Nutrition 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
206010040560 shock Diseases 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000000050 smooth muscle relaxant Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
210000005070 sphincter Anatomy 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
210000003523 substantia nigra Anatomy 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
230000035922 thirst Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
210000005239 tubule Anatomy 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000021542 voluntary musculoskeletal movement Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Food Science & Technology (AREA)
Polymers & Plastics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA000610329A 1989-09-05 1989-09-05 Methodes et compositions pour l'administration dose-effet non invasive de medicaments lipophiles Expired - Lifetime CA1339075C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000610329A CA1339075C (fr)	1989-09-05	1989-09-05	Methodes et compositions pour l'administration dose-effet non invasive de medicaments lipophiles

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000610329A CA1339075C (fr)	1989-09-05	1989-09-05	Methodes et compositions pour l'administration dose-effet non invasive de medicaments lipophiles

Publications (1)

Publication Number	Publication Date
CA1339075C true CA1339075C (fr)	1997-07-29

Family

ID=4140557

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000610329A Expired - Lifetime CA1339075C (fr)	1989-09-05	1989-09-05	Methodes et compositions pour l'administration dose-effet non invasive de medicaments lipophiles

Country Status (1)

Country	Link
CA (1)	CA1339075C (fr)

1989
- 1989-09-05 CA CA000610329A patent/CA1339075C/fr not_active Expired - Lifetime

Publication	Publication Date	Title
US4671953A (en)	1987-06-09	Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US5484602A (en)	1996-01-16	Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US5132114A (en)	1992-07-21	Compositions and methods of manufacture of compressed powder medicaments
US4863737A (en)	1989-09-05	Compositions and methods of manufacture of compressed powder medicaments
JP2717024B2 (ja)	1998-02-18	口腔溶解性薬剤組成物及びその製造方法
US6358060B2 (en)	2002-03-19	Two-stage transmucosal medicine delivery system for symptom relief
US6197334B1 (en)	2001-03-06	Lozenge and method of making
US6103257A (en)	2000-08-15	System for delivering pharmaceuticals to the buccal mucosa
CN1561214A (zh)	2005-01-05	新制剂及其用途
AU645966B2 (en)	1994-02-03	Method and compositions for noninvasive dose-to-effect administration of lipophilic drugs
CA1339075C (fr)	1997-07-29	Methodes et compositions pour l'administration dose-effet non invasive de medicaments lipophiles
AU684888B2 (en)	1998-01-08	Method and compositions for noninvasive dose to effect administration of lipophilic drugs
JP2801050B2 (ja)	1998-09-21	圧縮粉末薬剤
CA1339080C (fr)	1997-07-29	Methodes et compositions pour l'administration dose-effet non invasive de medicaments agissant au niveau cardiovascular ou renovasculaire
CA1339190C (fr)	1997-07-29	Compositions et methodes de fabrication de medicaments dans des poudres comprimees
US20040115244A1 (en)	2004-06-17	Methods and compositions for nicotine replacement therapy

Legal Events

Date	Code	Title	Description
2014-09-30	MKEX	Expiry	Effective date: 20140729